MedTrace Logo

Helsinki Ultra-acute Stroke Biomarker Study

NCT02145663 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1046

Last updated 2016-04-01

No results posted yet for this study

Summary

The aim of this study is to establish diagnostic and predictive biomarkers for patients with suspected acute stroke, that are transported by EMS as candidates for thrombolytic treatment. The study focuses on the ultra acute phase, \<4.5 hours from symptom onset, including the prehospital setting. Analyses will include known biomarkers (e.g. GFAP, NR2 peptide) and a discovery phase for novel markers. Patient outcome will be evaluated at 3 month using the modified Rankin Scale (mRS).

Conditions

  • Acute Stroke

Sponsors & Collaborators

  • HUS area Prehospital Emergency Service

    collaborator UNKNOWN

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Perttu Lindsberg, MD, PhD · Helsinki University Central Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-02-29

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145663 on ClinicalTrials.gov